Financial Statements Overview

Lonza at a Glance

 

ROIC in % 1

 m

CORE EBIT in CHF 1

 

Employees (Full-Time Equivalent) 1, 3

 m

CORE EBITDA in CHF 1

 

CORE EBITDA margin in % 1

 

CORE EBIT margin in % 1

> 

Nationalities

 m

Sales in CHF 1

 %

Sales Growth in % 1, 2

 

Active patent families 5

> 

Small 7 and large 8 molecules

 

Trademark filings 4

 

Brands 6

  1. Continuing Business, excluding the Specialty Ingredients business that was reclassified to discontinued operations

  2. Sales in constant exchange rate; in actual exchange rate: 7.2%

  3. Employees including the Specialty Ingredients business: 16,540

  4. Trademark filings including the Specialty Ingredients business; excluding: 2,360

  5. Active patent families including the Specialty Ingredients business; excluding: 406

  6. Brands including the Specialty Ingredients business; excluding: 270

  7. Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering

  8. Including mammalian, microbial, cell & gene therapy products and bioconjugates (applied protein services and drug product services are included for pre-clinical and clinical molecules only)

Historical Progression

Sales

Million CHF

This has images

ROIC

in %

This has images

CORE EBITDA

Million CHF

CORE EBITDA Margin

In %

This has images

Capital Expenditures (CAPEX)

Million CHF

CAPEX/Sales

In %

This has images

CORE EBIT

Million CHF

CORE EBIT Margin

In %

This has images

Net Debt/CORE EBITDA

Ratio

This has images
  1. Reported pro-forma 2017 financial results (restated for IFRS 15) include Capsugel full-year 2017 financial result

  2. Restated 2018 financial results reflect the classification of the Water Care business as discontinued operations

  3. Restated 2019 financial results reflect the classification of the Specialty Ingredients business as discontinued operations

  4. Continuing Business, excluding the Specialty Ingredients business that was reclassified to discontinued operations

  5. Based on Lonza Group figures, including discontinued operations

Ten-Year Overview of Major Highlights

Million CHF201120122013201420152016201720181201922020
Sales2,6923,9253,5843,6403,8034,1324,5485,5424,2074,508
CORE EBITDAn.a.6637117437939181,1961,5111,3341,406
Margin in %n.a.16.919.820.420.922.226.527.331.731.2
EBITDA5376456477377808481,0841,4291,2641,378
Margin in %19.916.418.120.220.520.523.825.830.030.6
CORE EBIT3263984364755246519041,1651,0441,095
Margin in %12.110.112.213.013.815.820.121.024.824.3
Result from operating activities (EBIT)261340253423428486673842825901
Margin in %9.78.77.111.611.311.814.815.219.620.0
CORE RONOA  in %n.a.8.812.314.316.421.530.031.432.128.9
RONOA in % 46.97.55.910.310.812.79.812.113.414.0
ROIC in % 3,4n.a.n.a.n.a.n.a.n.a.n.a.8.48.09.29.6
Net Operating Assets (NOA) 44,2053,9903,9164,0943,7393,7396,8526,7956,1666,411
CORE EPS (diluted) in CHF4.344.544.976.766.768.3810.7811.9811.4012.19
EPS (diluted) in CHF2.973.351.674.545.265.699.700.008.689.77
Operational free cash flow (bef. acquisitions)127510519476693638658884371504
Net debt 52,6472,3012,1032,0111,6601,5843,7623,5342,9612,813
Net debt /CORE EBITDA 5n.a.3.472.962.702.091.732.702.281.831.63
Number of employees (Full-Time Equivalent) 511,00110,7899,9359,8099,82910,13014,61815,37515,46816,540
  1. Lonza continuing operations, excluding the Water Care business classified as discontinued operations

  2. Restated to reflect the classification of the Specialty Ingredients business as discontinued operations (see note 5 from Financial Statements)

  3. Introduced in 2018, comparable data for 2017 was provided

  4. Refer to section “Alternative Performance Measures” of the Financial Report for more details on the calculation methodology

  5. “Net debt”, “Net debt/CORE EBITDA” and “Number of employees (Full-Time Equivalent)” reflect total group including discontinued operations